Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-08-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关联交易决策制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '关联交易决策制度' which translates to 'Related Party Transaction Decision System'. It details the company's internal rules and procedures for handling related party transactions, including definitions, decision-making authority, review and approval processes, and disclosure requirements. The content focuses on governance and compliance with regulatory rules from the Shanghai Stock Exchange and China Securities Regulatory Commission. There are no financial statements, earnings data, or audit results presented. The document is a governance policy or internal control document related to corporate governance practices. Therefore, it fits best under Governance Information (CGR). The document length (7390 characters) and detailed procedural content support this classification rather than a brief announcement or a financial report.
2025-08-28 Chinese
美迪西：股东会议事规则（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled "上海美迪西生物医药股份有限公司 股东会议事规则" which translates to "Shanghai Medicilon Inc. Shareholders Meeting Rules." The content extensively details the rules, procedures, and regulations governing the shareholders' meetings, including the powers of the shareholders' meeting, the convening of meetings, proposal submissions, voting procedures, and other governance-related matters. There is no indication that this is a report of financial results, audit, or any announcement of voting results. Instead, it is a governance document outlining internal rules and procedures related to shareholder meetings. Therefore, the document fits best under the category of Governance Information (CGR). The document length (15,000 characters) and detailed procedural content support this classification with high confidence.
2025-08-28 Chinese
美迪西：对外担保管理制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '对外担保管理制度' which translates to 'External Guarantee Management System' and is issued by Shanghai Medicilon Inc. It is a detailed internal policy document outlining the rules, procedures, responsibilities, and disclosure requirements related to the company's external guarantees. It references relevant laws and regulations, company bylaws, and governance procedures. The document is 6452 characters long, which is substantial and contains detailed procedural content rather than a brief announcement or summary. It does not contain financial statements, earnings data, or audit results, nor is it a transcript or presentation. It is a governance-related internal control document focused on managing external guarantees and risk control. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-28 Chinese
美迪西：董事会薪酬与考核委员会关于公司2025年限制性股票激励计划相关事项的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the company's 2025 restricted stock incentive plan. It discusses compliance with laws and regulations, eligibility of incentive recipients, and governance aspects related to the stock incentive plan. There is no financial data or report content, but rather a governance and remuneration-related disclosure about executive compensation plans. This fits the Remuneration Information category, which covers reports detailing compensation and incentive plans for executives and directors.
2025-08-28 Chinese
美迪西：2025年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled '上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划实施考核管理办法', which translates to 'Shanghai Medicilon Biopharmaceutical Co., Ltd. 2025 Restricted Stock Incentive Plan Implementation Assessment Management Measures'. It details the rules, principles, scope, performance assessment indicators, procedures, and management of the company's restricted stock incentive plan for 2025. The content focuses on governance and management of an equity incentive plan, including performance targets and assessment criteria for employees. There is no financial statement, earnings data, or regulatory filing of financial results. It is a governance-related document about internal rules and incentive mechanisms. Therefore, it fits best under Governance Information (CGR). The document length is 3102 characters, which is relatively short but contains substantive governance content rather than just an announcement or summary, so it is not an RPA or RNS. Hence, the classification is CGR with high confidence.
2025-08-28 Chinese
美迪西：独立董事工作制度（2025年8月修订）
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, responsibilities, nomination, election, and duties of independent directors within the company. It references company governance, legal and regulatory requirements, and internal company rules. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance practices and internal rules related to board members, specifically independent directors. This aligns with the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2025-08-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.